SCHEMBL1785947

SCHEMBL1785947

NC(=O)c1cc(N2CCOCC2)c(Cl)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
GAA P10253 1/20 0.51
LMNA P02545 3/20 0.49
HTT P42858 3/20 0.49
MAPK1 P28482 2/20 0.49
HPGD P15428 2/20 0.48
KDM4E B2RXH2 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CASP1 P29466 1/20 0.48
CYP2C19 P33261 1/20 0.48
ALDH3A1 P30838 1/20 0.48
ALDH1A3 P47895 1/20 0.48
RAB9A P51151 3/20 0.47
AKR1C3 P42330 1/20 0.47
PKM P14618 1/20 0.46
SYK P43405 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12316376 0.85 HSP90AA1 (0.51) MAPTSMN1; SMN2GAALMNAHTT
SCHEMBL1787489 0.83 MAPK10 (0.51) MAPTSMN1; SMN2LMNAMAPK1HPGD
SCHEMBL1790337 0.81 ALDH1A1 (0.49) MAPTSMN1; SMN2GAALMNAHTT
SCHEMBL12316379 0.80 MAPT (0.47) MAPTSMN1; SMN2GAALMNAHTT
SCHEMBL2744730 0.78 SMN1; SMN2 (0.59) MAPTSMN1; SMN2GAALMNAHTT
SCHEMBL7449213 0.77 AKR1C3 (0.56) MAPTSMN1; SMN2GAALMNAHTT
SCHEMBL1785668 0.77 MAPT (0.54) MAPTSMN1; SMN2GAALMNAHTT
Lithium Ion SCHEMBL31739817 0.77 MAPT (0.54) MAPTSMN1; SMN2GAALMNAHTT
SCHEMBL827916 0.75 ALDH1A1 (0.48) MAPTSMN1; SMN2LMNAHTTHPGD
SCHEMBL8145983 0.74 MAPT (0.50) MAPTSMN1; SMN2GAALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2013-08-08 US disclosed
EP-2607357-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS Astrazeneca AB (SE) 2013-06-26 EP disclosed
US-20120115845-A1 THERAPEUTIC AGENTS ALLEN JACK MCQUEEN (GB) 2012-05-10 US disclosed
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2011-05-26 US disclosed
EP-2205576-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS AstraZeneca AB (SE) 2010-07-14 EP disclosed
US-20090186870-A1 Therapeutic Agents - 802 ASTRAZENECA AB (SE) 2009-07-23 US disclosed
WO-2009047558-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2009-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203730-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MAPT 3413/4885SMN1; SMN2 1984/4885GAA 1879/4885
US-20120115845-A1 THERAPEUTIC AGENTS GPR119, MC2R, MC4R MAPT 4086/4885SMN1; SMN2 913/4885GAA 402/4885
US-20090186870-A1 Therapeutic Agents - 802 GPR119, SLC5A2, MC2R MAPT 4300/4885SMN1; SMN2 813/4885GAA 549/4885
US-20110124621-A1 BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS GPR119, GHSR, GLP1R MAPT 3413/4885SMN1; SMN2 1984/4885GAA 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.